Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.
Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM).
Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM).
Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo.
Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products.
Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.”
Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities
Laidlaw Capital Markets is pleased to have Co-Managed the $655,000,000 Guggenheim Active Allocation Trust offering alongside Bank of America, Morgan Stanley, & Wells Fargo.
Laidlaw Capital Markets is pleased to have Co-Managed the $2,040,000 Blackrock ESG Capital Allocation Trust offering alongside Bank of America, Morgan Stanley, UBS, & Wells Fargo
Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma’s (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC.
The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies (BSGM). We are proud to have raised approximately $40,000,000 for BioSig over the course of our decade long relationship and look forward to watch the company continue to execute.
Read Article: https://ir.biosig.com/press-releases/detail/278/biosig-announces-closing-of-public-offering-of-common-stock
Independent advisor platforms are attracting a growing number of international advisors to their networks. What is driving this growth and what are the benefits for advisors who opt for this independent model?
The entrepreneurial spirit is strong in the advisory industry, with a growing number of international advisors now making the jump to independence. But launching an RIA can prove a time-consuming and costly venture that also requires negotiating crucial third-party agreements with a range of service providers.
Read Full Article Here
This link is provided as a service to you, and will take you to a third party site not affiliated with this site. We are not responsible for the content and do not guarantee the accuracy of any information or material contained therein Laidlaw & Company provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by Laidlaw & Company, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL